Partial Resurfacing of the Knee with the BioPoly Implant

Interim Report at 2 Years

Dinesh Nathwani, MB, ChB, MSc, FRCS(Tr&Orth),
Michael McNicholas, BSc, MB, ChB, FCES(Ed&Glasg), MD, FRCS(Tr&Orth), FFSEM RCSI,
Alister Hart, MA, MD, FRCSSG(Orth), Jonathan Miles, MD, FCSS(Orth), and Vladimir Bobič, MD, FRCS(Ed)

Investigation performed at Imperial College Healthcare NHS Trust – Charing Cross Hospital, The London Clinic, London; Aintree University Hospital, Liverpool; Royal National Orthopaedic Hospital, Stanmore; and Nuffield Health, The Grosvenor Hospital Chester, Chester, United Kingdom

Background: Current treatments for focal chondral and osteochondral lesions of the femoral condyle have been associated with variable outcomes. We conducted a clinical trial of the BioPoly RS Partial Resurfacing Knee Implant to address this unmet need.

Methods: We performed a single-arm, prospective study in which 33 patients with focal cartilage lesions affecting the femoral condyle were managed with the BioPoly RS Partial Resurfacing Knee Implant. Knee injury and Osteoarthritis Outcome Score (KOOS) scores, a visual analog scale (VAS) for pain, the Short Form-36 (SF-36) physical component score, and the Tegner activity score were used to assess outcomes preoperatively and at 6 months, 1 year, and 2 years postoperatively. The KOOS outcomes at 2 years were compared with historical outcomes following microfracture treatment.

Results: We found significant and clinically meaningful improvements in the KOOS scores, VAS pain score, and SF-36 physical component score (p < 0.025) when the values at all 3 postoperative time points were compared with the preoperative scores, and we also found significant improvements when the Tegner activity score at 2 years was compared with the preoperative score (p < 0.025). More than half of the cohort of patients had had a previous failure of cartilage-repair procedures. No significant differences were detected between younger patients (≤40 years) and older patients (>40 years). When compared with historical microfracture data, the BioPoly RS Implant demonstrated significantly superior KOOS scores for quality of life and sports.

Conclusions: The present study indicated that the BioPoly RS Partial Resurfacing Knee Implant is safe, that it resulted in significantly improved knee function by 6 months, and that this improvement was sustained for 2 years regardless of patient age. The BioPoly RS Knee Implant allows return to a higher level of sporting activity than microfracture. Additional long-term follow-up is needed to determine the long-term effects of the device.

Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Disclosure: The study was funded by BioPoly LLC. Investigators and patients received no compensation for their participation in the study other than reimbursement for study-related travel from a long distance. On the Disclosure of Potential Conflicts of Interest forms, which are provided with the online version of the article, one or more of the authors checked “yes” to indicate that the author had a relevant financial relationship in the biomedical arena outside the submitted work (http://links.lww.com/JBJSOA/A5).

Copyright © 2017 The Authors. Published by The Journal of Bone and Joint Surgery, Incorporated. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
disabling and can result in a large economic burden due to both direct costs (e.g., hospital stay and insurance expenditure) and indirect costs (e.g., lost productivity and early retirement)\(^7\).

While current late-stage treatments for cartilage defects in the knee (i.e., total or partial knee arthroplasty) have provided consistent, positive outcomes for elderly patients\(^8\), the use in patients <55 years of age has become controversial because of concerns regarding implant longevity\(^9\)\(^-\)\(^12\). As a result, biological treatments such as microfracture, the osteochondral autograft transfer system (OATS), autologous chondrocyte implantation (ACI), and matrix-induced ACI (MACI) are used in active younger and middle-aged patients\(^13\). Most of these treatments have not demonstrated sustainable, consistent results\(^14\)\(^-\)\(^16\), and some require long postoperative rehabilitation\(^17\). In addition, the magnitude of the positive impact of biological treatments appears to significantly decrease with increasing patient age and when used for revision after the failure of previous biological treatments\(^18\)\(^-\)\(^23\).

The BioPoly RS Partial Resurfacing Knee Implant was developed as an early intervention and treatment for patients with cartilage lesions who want to delay or eliminate the need for total or partial arthroplasty and quickly return to full activity. BioPoly is a biosynthetic implant that is manufactured from a combination of ultra-high molecular weight polyethylene (UHMWPE) and hyaluronic acid (HA) that is designed to be less dependent on patient biology and to require less rehabilitation time, with less bone resection in comparison with partial or total arthroplasty.

The objectives of the present study were (1) to assess clinical outcomes and complications after treatment with the BioPoly Knee Implant and (2) to compare clinical outcomes

### TABLE I Inclusion and Exclusion Criteria

<table>
<thead>
<tr>
<th>Inclusion Criteria*</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 21 years and older</td>
<td>Body mass index (BMI) ≥30 kg/m(^2)</td>
</tr>
<tr>
<td>Symptomatic femoral condyle lesions classified as ICRS grade 2, 3, or 4</td>
<td>Generalized degenerative or autoimmune arthritis</td>
</tr>
<tr>
<td>Femoral condyle lesion size ≤3.1 cm(^2) circumscribed by normal or nearly-normal (ICRS grade-0 or 1) cartilage with an overall depth ≤4 mm from the articulating surface</td>
<td>Gout</td>
</tr>
<tr>
<td>Sufficient subchondral bone quality to support implant</td>
<td>Uncorrected chronic malalignment of the knee†</td>
</tr>
<tr>
<td>Understanding and willingness to comply with postoperative rehabilitation instructions and follow-up visits</td>
<td>Uncorrected ligamentous instability†</td>
</tr>
<tr>
<td></td>
<td>Uncorrected mechanically symptomatic meniscal tear or total meniscectomy†</td>
</tr>
<tr>
<td></td>
<td>Kissing lesion on tibia</td>
</tr>
<tr>
<td></td>
<td>&gt;1 implant required to accommodate lesion</td>
</tr>
<tr>
<td></td>
<td>Patient-reported allergy to titanium alloy (Ti-6Al-4V), ultra-high molecular weight polyethylene (UHMWPE), or hyaluronan/hyaluronic acid (HA)</td>
</tr>
<tr>
<td></td>
<td>Use with opposing articulating tibial components</td>
</tr>
<tr>
<td></td>
<td>Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the affected knee</td>
</tr>
<tr>
<td></td>
<td>Pregnant, prisoner, vulnerable population, unable to provide informed consent</td>
</tr>
</tbody>
</table>

*ICRS = International Cartilage Repair Society. †If corrected during surgery, BioPoly implantation was not excluded.

---

Fig. 1

**Fig 1-A** Intraoperative photograph made during the implantation of a BioPoly RS Partial Resurfacing Knee Implant in the femoral condyle. **Fig. 1-B** Photograph showing the different sizes of the BioPoly RS Partial Resurfacing Knee Implant.
after such treatment with those after treatment with microfracture as reported in the historical literature.

Materials and Methods

We designed a multi-center, single-arm, historically controlled clinical investigation for the purposes of (1) comparing clinical outcomes between the BioPoly RS Knee Implant and microfracture (based on historical literature) and (2) comparing the postoperative clinical outcomes with preoperative findings. The primary end points were Knee Injury and Osteoarthritis Outcome Score (KOOS)\(^\text{26}\) overall score and subscores, a visual analog scale (VAS)\(^\text{27}\) score for pain, the Short Form-36 (SF-36)\(^\text{28}\) physical component score, and the Tegner activity\(^\text{29}\) score at 2 years. While the focus of this interim report is current patient outcomes at 2-year follow-up, patients will eventually be followed to 5 years.

The study was conducted at 5 centers in the United Kingdom, and Good Clinical Practice guidelines were followed. With the level of significance established at \(p < 0.025\) and power set at 0.90, the number of patients required for study enrollment was determined to be 35 in order to demonstrate noninferiority with the mean 18-month KOOS quality-of-life score of a historical microfracture control with an anticipated similar patient population\(^*\). In order to make valid comparisons with the results for historical microfracture controls, a literature review was conducted with use of specific keywords and the identified articles were evaluated for suitability with use of a methodological grading system. Forty-five articles were identified on the basis of the literature review, and these articles were graded according to the level of evidence, comparability of KOOS data, and similarity to the current study in terms of follow-up and inclusion/exclusion criteria. With use of this system, 4 sources of microfracture data were identified as appropriate for use as historical controls\(^\text{21,28-30}\). Informed consent was obtained for all patients, and the clinical protocol and informed consent were approved by the Cambridge Central Research Ethics Committee (REC11/EE/0256). Patients with symptomatic focal cartilage defects on the weight-bearing region of the medial or lateral femoral condyle were enrolled according to specific inclusion and exclusion criteria (Table I).

TABLE II Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of patients</th>
<th>Mean ± Standard Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>33</td>
<td>42.7 ± 11.6</td>
</tr>
<tr>
<td>Age ≤40 years (no. of patients)</td>
<td>13</td>
<td>(39.4%)</td>
</tr>
<tr>
<td>Previous knee surgery (no. of patients)</td>
<td>25</td>
<td>(75.8%)</td>
</tr>
<tr>
<td>Cartilage repair (no. of patients)</td>
<td>19</td>
<td>(57.6%)</td>
</tr>
<tr>
<td>Other knee surgery (no. of patients)</td>
<td>15</td>
<td>(45.5%)</td>
</tr>
<tr>
<td>Contralateral knee status normal/nearly normal (no. of patients)</td>
<td>21</td>
<td>(63.6%)</td>
</tr>
<tr>
<td>Body mass index (kg/m(^2))</td>
<td>26.7 ± 3.8</td>
<td></td>
</tr>
<tr>
<td>Defect size (cm(^2))</td>
<td>2.7 ± 0.6</td>
<td></td>
</tr>
<tr>
<td>Involved knee (right/left)</td>
<td>39.4%/60.6%</td>
<td></td>
</tr>
<tr>
<td>Involved compartment (medial/lateral)</td>
<td>75.8%/24.2%</td>
<td></td>
</tr>
<tr>
<td>Type of injury (no. of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nontraumatic, gradual</td>
<td>13</td>
<td>(39.4%)</td>
</tr>
<tr>
<td>Traumatic, noncontact</td>
<td>8</td>
<td>(24.2%)</td>
</tr>
<tr>
<td>Traumatic, contact</td>
<td>6</td>
<td>(18.2%)</td>
</tr>
<tr>
<td>Activity at injury (activities of daily living/sports)</td>
<td>33.3%/33.3%</td>
<td></td>
</tr>
</tbody>
</table>

*The values are given as the mean and the standard deviation. †Including microfracture, ACI, MACI, and OATS. In addition, 9 patients had other knee surgery. ‡Other knee surgery includes meniscal, ligamentous, patellofemoral surgery, or cartilage-shaving surgery. §Defect size after debridement and implant preparation.
were used to examine for significant differences. Age-related differences were also investigated with 2-sample, 1-tailed t tests for the overall KOOS score, the SF-36 physical component score, and the VAS pain score (α = 0.05). KOOS clinical outcome scores were compared with those in 4 recent microfracture studies\(^21,28-30\) with use of 2-sample, 1-tailed t tests (α = 0.025), and KOOS quality-of-life outcome scores were compared with those in 1 of the studies\(^28\) with use of a noninferiority test (margin = 10, α = 0.025) as established in the protocol. Any missing data were queried and resolved.

### Patient Population

A total of 40 patients were enrolled and screened over 3 years (Fig. 2). Five patients were withdrawn before surgery because of failed screening or patient withdrawal. Two patients were withdrawn during surgery but before implantation of the BioPoly device. The first patient was withdrawn because of a tibial kissing lesion, and the second was withdrawn because of a larger-than-expected cartilage lesion. Within the treated group, 2 patients were withdrawn before 6 months because of protocol deviations. The first patient was withdrawn because of an existing spinal tumor that was not disclosed when the patient answered exclusion criteria screening questions before surgery, and the second patient was withdrawn because 2 implantations were performed in the same knee (in the medial and lateral condyles) within a period of 3 months.

In the treated population, approximately 30% required the 15-mm implant, 35% required the 20-mm implant, and 35% required the 15 × 24-mm implant. The mean age of the patients was 42.7 years (range, 22 to 65 years), and the intraoperative defect sizes ranged from 0.6 to 3.1 cm\(^2\). Interestingly, the majority (58%) of the cohort had had previous cartilage-repair surgery. No implant. The mean age of the patients was 42.7 years (range, 22 to 65 years), and the intraoperative defect sizes ranged from 0.6 to 3.1 cm\(^2\). Interestingly, the majority (58%) of the cohort had had previous cartilage-repair surgery. No

### Implant Safety

No device-related adverse events were reported. The majority (86%) of reported adverse events were of mild or moderate severity, and all severe or serious adverse events improved or resolved. The most common adverse event was knee pain (arthralgia) (9 patients, with the pain being localized to the contralateral compartment in 4 of these patients). Additional adverse events included wound infection (1 patient), stiffness (1 patient), swelling (2 patients), crepitation (3 patients), and a loose cartilage body (1 patient). The loose cartilage body, which was identified in the operatively treated knee 4 months postoperatively, necessitated arthroscopic surgery but was not related to the implant. In fact, at that time, the implant was assessed and was deemed to be functioning and well fixed. One patient underwent revision after the 2-year follow-up because of the failure of osseointegration. This patient had had failures of previous microfracture and ACI operations, which may have resulted in inadequate subchondral bone metabolism. However, other patients who had had failures of previous cartilage-repair procedures did not have failure of osseointegration. The patient who underwent revision was managed with an alternative biological treatment.

### Results

#### Clinical Outcomes

At 6 months, 1 year, and 2 years after surgery, knee function (assessed with the KOOS) demonstrated significant (p < 0.025) and clinically meaningful improvement (difference, >8 to 10 points)\(^22\) in comparison with preoperative function. At all 3 of these time points, there was also significant improvement

---

**TABLE III Patient-Reported Outcome Scores at 6 Months, 1 Year, and 2 Years**

<table>
<thead>
<tr>
<th></th>
<th>Preop. (N = 33)</th>
<th>6 Mo (N = 24)</th>
<th>1 Yr (N = 22)</th>
<th>2 Yr (N = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KOOS overall</td>
<td>44.9 ± 18.0†</td>
<td>67.9 ± 15.9</td>
<td>67.3 ± 18.9</td>
<td>77.6 ± 16.6</td>
</tr>
<tr>
<td>Pain</td>
<td>51.9 ± 20.4†</td>
<td>76.9 ± 14.9</td>
<td>75.6 ± 18.5</td>
<td>81.2 ± 16.2</td>
</tr>
<tr>
<td>Quality of life</td>
<td>22.2 ± 18.4†</td>
<td>50.8 ± 26.7</td>
<td>48.9 ± 26.7</td>
<td>68.2 ± 22.5</td>
</tr>
<tr>
<td>Sports</td>
<td>30.0 ± 27.4†</td>
<td>56.9 ± 22.1</td>
<td>56.4 ± 29.3</td>
<td>69.2 ± 25.8</td>
</tr>
<tr>
<td>Activities of daily living</td>
<td>64.2 ± 24.3†</td>
<td>84.9 ± 14.3</td>
<td>84.4 ± 16.1</td>
<td>89.0 ± 15.7</td>
</tr>
<tr>
<td>Symptoms</td>
<td>56.2 ± 20.6†</td>
<td>70.2 ± 18.0</td>
<td>71.3 ± 19.2</td>
<td>80.4 ± 12.9</td>
</tr>
<tr>
<td>VAS pain</td>
<td>4.1 ± 2.5†</td>
<td>2.4 ± 2.4</td>
<td>2.0 ± 2.0</td>
<td>1.4 ± 2.2</td>
</tr>
<tr>
<td>SF-36 physical component</td>
<td>42.3 ± 32.0†</td>
<td>69.7 ± 28.2</td>
<td>71.0 ± 27.7</td>
<td>81.9 ± 30.8</td>
</tr>
<tr>
<td>Tegner activity</td>
<td>2.5 ± 1.7†</td>
<td>3.3 ± 1.4</td>
<td>3.1 ± 1.9</td>
<td>4.0 ± 1.9</td>
</tr>
</tbody>
</table>

*All values are given as the mean and the standard deviation. †P < 0.025 compared with scores at 6 months, 1 year, and 2 years. ‡P < 0.025 compared with score at 2 years.

---

**Fig. 3**

Bar graph showing the mean overall KOOS scores for younger patients (≤40 years old) and older patients (>40 years old). No significant differences were found between these age groups (p > 0.05). The I-bars indicate the standard error.
(p < 0.025) in the VAS pain score and the SF-36 physical component score in comparison with the preoperative scores (Table III). At 2 years after surgery, there was significant improvement (p < 0.025) in the Tegner activity score. At the time of this progress report, 24, 22, and 12 patients had reached the 6-month, 1-year, and 2-year time points, respectively.

In order to evaluate the potential effects of age, the outcomes for younger patients (≤40 years old) were compared with those for older patients (>40 years old). Interestingly, no significant differences were detected between these 2 groups in terms of the overall KOOS (Fig. 3), VAS pain score, or SF-36 physical component score (p > 0.05); however, the sample size was limited at the later time points.

The BioPoly Knee Implant demonstrated noninferiority (p < 0.025) in terms of the KOOS quality-of-life score when compared with microfracture data28.

The BioPoly RS Partial Resurfacing Knee Implant demonstrated improved clinical outcomes in comparison...
with historical outcomes following microfracture treatment as reported in multiple studies\textsuperscript{21,28–30}. When the 2-year mean KOOS subscores were compared with microfracture data from the literature, the BioPoly implant demonstrated superior clinical outcomes in terms of quality of life and sports and demonstrated similar clinical outcomes in terms of activities of daily living, pain, and symptoms (Fig. 4). Quality of life and sports are recognized as the most discerning KOOS domains for the assessment of treatment impact. This observation was verified by statistical testing, which demonstrated that the BioPoly implant yielded significantly superior (p < 0.025) outcomes in terms of quality of life when compared with all of the microfracture studies and demonstrated significantly superior outcomes (p < 0.025) in terms of sports and activities of daily living when compared with some of the microfracture studies.

Further examination of the KOOS quality-of-life data showed that the preoperative scores for the patients managed with the BioPoly implant were similar to those for the patients in the microfracture studies whereas the 2-year scores associated with the BioPoly implant were significantly superior (p < 0.025) to those in all of the microfracture studies (Fig. 5). The average age of the patients managed with the BioPoly implant in the present study was 7 to 9 years greater than that of the patients in the microfracture studies.

\textbf{Radiographic Observations}
Radiographically, it was observed that implants were stable after 6 months, 1 year, and 2 years. Integration with surrounding bone was observed, with no evidence of radiolucency or implant migration (Fig. 6).

\textbf{Discussion}
We observed that the BioPoly RS Partial Resurfacing Knee Implant is safe, that it resulted in significantly improved patient outcomes by 6 months, and that this improvement was sustained for 2 years, regardless of patient age (range, 22 to 65 years). Significant improvement was seen at 6 months for the overall KOOS (and all individual subscores), the VAS pain score, and the SF-36 physical component score. This improvement was maintained through 2 years, and the Tegner activity score demonstrated significant improvement at 2 years. Over half of the patients had had a failure of previous cartilage-repair procedures, and no significant differences in outcome scores were observed between younger and older patients. Radiographic evaluation demonstrated adequate device fixation and integration with surrounding bone. There were no serious, device-related adverse events. There was 1 revision, which occurred after the 2-year follow-up. The BioPoly Knee Implant demonstrated significantly improveable outcomes, which were maintained over the 2-year follow-up period.

---

\textsuperscript{21,28–30}
superior KOOS quality-of-life scores at 2 years when compared with the historical outcomes of microfracture treatment as reported in the literature. The patients who were managed with the BioPoly implant were an average of 7 to 9 years older than those who were managed with microfracture.

Total knee arthroplasty has been extensively studied and has been shown to be consistently effective in older patients, with 20-year survival rates of as high as 97.8%. Patients ≤55 years old, however, present a challenge because they often desire to return to strenuous physical activity postoperatively, which is not recommended as part of the rehabilitation process and could increase implant wear and decrease implant longevity. Studies have shown decreased short and long-term implant-survival rates for younger patients, and 1 study demonstrated a 10-year revision rate of 16% in association with wear and/or osteolysis in younger patients. A series of total knee arthroplasty patients <50 years of age, a 2-year revision rate of 9% was reported.

Biological treatments, meanwhile, have been examined for use in active younger and middle-aged patients, but these treatments have not demonstrated sustainable, consistent results and require long postoperative rehabilitation. Microfracture is currently the most common biological treatment for the repair of early-stage focal defects, but tissue quality and outcomes consistently have been shown to deteriorate over time (typically beginning at 18 to 36 months) along with increases in the failure rate. ACI, MACI, and OATS also have been examined; however, studies have shown more positive outcomes for younger patients compared with middle-aged patients. Those treatments also have been shown to be prone to failure in patients who have already had previous microfracture surgery, but that finding has not been reported in all studies.

The hydrophilic, low-wear properties of the BioPoly implant material have been shown in long-term, large-animal studies. This hydrophilic capability is illustrated by comparing the appearance of a water droplet on ultra-high molecular weight polyethylene with that on the BioPoly surface. It is notable that the BioPoly RS Knee Implant did not demonstrate outcome differences between younger and older patients. Mithoefer et al. examined 48 patients who were managed with microfracture and reported that a number of outcomes showed significant improvements after the microfracture treatment. It was noted, however, that there was a trend toward better outcomes in patients who were ≥50 years of age. It is also interesting to note that while the BioPoly implant demonstrated similar KOOS outcomes in terms of pain, activities of daily living, and symptoms when compared with microfracture studies, it demonstrated superior outcomes in terms of KOOS quality-of-life and sports scores. A possible explanation for this effect is that patients who are managed with microfracture are forced to accept a less-active lifestyle in order to mitigate knee pain and symptoms, whereas those who are managed with the BioPoly implant are able to regain their previous active lifestyle, as evidenced by increasing Tegner scores (Table III). Another possible factor could be the rehabilitation protocol for the BioPoly implant, which allows patients to immediately bear weight and return to activity more quickly than does a standard microfracture rehabilitation protocol.

Of the recent microfracture studies that were analyzed in the present study, the 2008 study by Saris et al. had the most similar patient population to our cohort, except that the average age in that study was 8 years lower than that in the present study. In that study, 61 patients with an average age of 33.9 years were managed with microfracture (average lesion size, 2.4 cm²). The authors found no significant differences between the outcomes of cultured chondrocyte implantation and those of microfracture. The average KOOS quality-of-life score in the present study was significantly superior to that for the microfracture arm in the study by Saris et al. (68.2 compared with 52.54; p = 0.022).

The limitations of the present study include the lack of long-term clinical outcomes, the use of patient-reported outcome measures, and a comparatively small sample size. The lack of long-term outcomes can primarily be attributed to the recent release of the device.

While there is a need for longer-term clinical studies of the BioPoly RS Partial Resurfacing Knee Implant, the present short-term study demonstrated significant improvement in patient-reported outcomes and an exceptional safety profile for the device out to 2 years.

Appendix

A table showing the 4-phase rehabilitation protocol is available with the online version of this article at jbjs.org (http://links.lww.com/JBJSOA/A6).

Dinesh Nathwani, MB, ChB, MSc, FRCS(Tr&Orth)
Michael McNicholas, BSc, MB, ChB, FCRS(Ed&Glasg), MD, FRCS(Tr&Orth), FFSEM RCS(Eng)
Alister Hart, MA, MD, FRCS(Orth)
Jonathan Miles, MD, FCRS(Orth)
Vladimir Bobić, MD, FRCS(Eng)

1Imperial College Healthcare NHS Trust and The London Clinic, London, United Kingdom
2Aintree University Hospital NHS Trust, Liverpool, United Kingdom
3Royal National Orthopaedic Hospital, Stanmore, United Kingdom
4University College London, London, United Kingdom
5Chester Knee Clinic, Nuffield Health, The Grosvenor Hospital, Chester, United Kingdom

E-mail address for V. Bobić: vbobic@kneeclinic.info
References


